After a lengthy downturn, renewed optimism is building among young drugmakers and their backers as a new funding wave takes shape, said Santé Ventures’ Omar Khalil.

Salspera has set out plans for a $91 million IPO to fund the phase 3 study of its bacteria-based cancer therapy. | Salspera has set out plans for a $91 million IPO to fund the phase 3 study of its ...

BioVie is eyeing a $19.7 million IPO for a spinout focused on bringing a new formulation of an approved kidney failure drug to market as a potential treatment for liver disease. | BioVie is eyeing a ...

Biotech IPOs fell to a decade low in 2025 Investors expect more listings amid easing rate pressure Policy clarity under Trump has reduced worst-case fears Late-stage drug pipelines drawing renewed ...

With an oversubscribed trading debut now in the books, Veradermics—developing an oral version of the molecule behind Rogaine—is well coiffed to tap into the increasingly lush opportunity for hair ...

Two withdrawals of recently submitted initial public offering (IPO) filings by drug developers, plus a dearth of new filings this month, suggest that the outlook for biopharma IPOs remains cloudy, ...

For all of the benefit that radiopharmaceuticals offer, these treatments currently address a limited number of cancer targets. Aktis Oncology has technology that could broaden the reach of this type ...

Allison DeAngelis is the East Coast biotech and venture capital reporter at STAT, reporting where scientific ideas and money meet. She is also co-host of the weekly biotech podcast, The Readout Loud.

For full-year 2025, 58 biotech deals worth $65.9 billion were completed compared with 73 deals worth $109 billion in all of 2024. This represents a major decline in total dollar volume and the number ...

Gilead has penned a potential $1.5 billion synthetic lethality deal with a Chinese biotech. A cell therapy company could end a one-year-plus biotech IPO drought in Tokyo. Novo Nordisk faces increased ...

"We are also seeing improvement in US biotech funding, as well as higher M&A and IPO activity, which are leading indicators ...

Chungui International BioTech Group has filed for an initial public offering. The consumer goods company said it will sell 3 million units at $5 apiece, according to a filing with the Securities and ...